Holiday book sale: Save up to 30% on print and eBooks. No promo code needed.
Save up to 30% on print and eBooks.
Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies
1st Edition - December 30, 2014
Editors: Manmohan Singh, Maya Salnikova
Hardback ISBN:9780124166035
9 7 8 - 0 - 1 2 - 4 1 6 6 0 3 - 5
eBook ISBN:9780124166615
9 7 8 - 0 - 1 2 - 4 1 6 6 6 1 - 5
Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies takes a look at the current strategies, successes and challenges involved with the development of… Read more
Purchase options
LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies takes a look at the current strategies, successes and challenges involved with the development of novel formulations of biologics, vaccines and cancer therapy. This thorough reference on the latest trends in the development of diverse modalities will appeal to a broad community of scientists, students and clinicians. Written by leading authors across academia and industry, this book covers important topics such as unique drug delivery devices, non-parenteral delivery trends, novel approaches to the treatment of cancer, immunotherapy and more. It includes real-world cases and examples which highlight formulations with therapeutic proteins, monoclonal antibodies, peptides and biobetters, as well as cases on novel vaccines formulations including evolving pathogens, novel modalities of vaccines, universal vaccines. This book is a thorough and useful resource on the development of novel biologics, vaccines and cancer therapies.
Provides strategies for the development of safe and efficacious novel formulations for various modalities of biologics, vaccines and for cancer therapy
Highlights novel cases from current clinical trials as well as marketed products
Reviews overall successes and challenges in the development of novel formulations, including new molecular targets for the treatment of diseases, design of target-specific therapies, regulatory considerations, individualized therapies
Researchers, clinicians and students working in formulation, drug delivery, biotechnology, oncology, personalized medicine, immunology, parenteral devices and systems and molecular biology
List of Contributors
Preface
Section I: Novel therapeutic approaches
Chapter 1: Clinical Considerations in the Design, Evaluation, and Development of Novel Therapies
Abstract
Introduction
Scientific challenges in the design of effective pharmacological and biological compounds
Changes in the current landscape of clinical development evaluation for novel therapies
Influencing and changing the status quo: considerations in the clinical development of future therapies
Chapter 2: New Era in Gene Therapy
Abstract
Introduction
Non-viral vectors
Viral vectors
Genomics and epigenomics in drug discovery
Clinical trials
Conclusion and future prospects
Chapter 3: Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems
Abstract
Introduction to Nanomedicine
Strategies for preferential accumulation of nanoparticles
Next-generation drug delivery platforms
Implants
Chapter 4: Novel Approaches for the Delivery of Biologics to the Central Nervous System
Abstract
The rising global burden of central nervous system disorders
Challenges in CNS drug development
Clinical strategies in CNS delivery for overcoming the blood–brain barrier
New directions in CNS delivery
Conclusion
Chapter 5: Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies
Abstract
Introduction
Formulation aspects of biologics and vaccines
Routes for administration of biologics, vaccines, and cancer therapies
Chemotherapy versus immunotherapy
Current immune therapies
Combination of immunotherapy and chemotherapy
Microparticle-based delivery systems for nonparenteral delivery of bacterial (meningococcal) vaccines
Influenza vaccine
Human papillomavirus vaccine
Cancer vaccine case studies
Overall summary and conclusions
Section II: Novel approaches for biologics
Chapter 6: Novel Generation of Antibody-Based Therapeutics
Chapter 7: Novel Approaches in Discovery and Design of Antibody-Based Therapeutics
Abstract
Introduction
Antibody discovery and optimization via data mining
Species other than humans and rodents as source of V regions
Bi- and multispecifics inspired in the modularity of antibodies
Conclusions
Acknowledgments
Chapter 8: Novel Therapeutic Proteins and Peptides
Abstract
Introduction
Innovation in recombinant therapeutic proteins and peptides
Innovation in synthetic therapeutics peptides
Novel opportunities for biologics
Chapter 9: Biobetter Biologics
Abstract
Introduction
Emerging trends in developing biobetter biologics
Manufacturing process improvements
Conclusions
Acknowledgments
Section III: Novel approaches for vaccines
Chapter 10: Vaccines Against Non-Infectious, Non-Cancer Novel Targets
Abstract
Overview of non-infectious, non-cancer vaccine targets
Reproductive system
Neuroendocrine system
Immune system
Future trends
Conclusions
Chapter 11: Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines
Abstract
Seasonal and pandemic influenza vaccines
Human immunodeficiency virus vaccines
Dengue vaccines
Streptococcus pneumoniae vaccines
Development of novel adjuvants
Chapter 12: Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field
Abstract
Introduction
Immunity to HIV-1
Landscape of HIV-1 vaccines
Principles of prime-boost vaccination
DNA prime-boost strategies
Pox viral prime-boost strategies
Other viral vector prime-boost vaccination strategies
Mucosal immunity and prime-boost vaccination approaches
Importance of HIV-specific T- and B-cell avidity and novel HIV-1 prime-boost vaccination strategies
Conclusions
Section IV: Novel approaches for cancer therapies
IV.I: Novel Therapeutic Approaches and Targets for Cancer
Chapter 13: Personalized Therapies for Cancer Treatment
Abstract
Introduction
The Cancer Genome Atlas
High-throughput technologies
Using targeted therapy to personalize cancer treatment
Personalized therapy for breast cancer: are we there yet?
Chapter 14: Hunting Molecular Targets for Anticancer Reagents by Chemical Proteomics
Abstract
Introduction
Chemical proteomics strategies
Chemical proteomic-based quantification
Systematic and Efficacious Target Identification
Conclusions
IV.II: Novel Immunotherapies for Cancer
Chapter 15: Cancer Vaccines
Abstract
Introduction
Limited potency of cancer vaccines
Vaccine platforms
Limited clinical efficacy of cancer vaccines
New trends in vaccine strategies
Summary
Chapter 16: T-Cell Immunotherapy for Cancer
Abstract
Brief history of T-cell therapy
Tumor-infiltrating lymphocytes
Antigen-Specific T cells
Genetically modified T Cells
Challenges in T-cell immunotherapies
Summary
Chapter 17: Immunostimulators and Immunomodulators in Cancer Treatment
Abstract
Cytokines and cancer therapy
Oncolytic viruses
Checkpoint inhibitors
Importance of the Th1/Th2 response in cancer immunotherapy
IV.III: Novel Approaches for Cancer Therapy with Small Molecules
Chapter 18: Long-Circulating Therapies for Cancer Treatment
Abstract
Introduction: consideration of nanotechnology for cancer therapy
Challenges in rational design of nanocarriers: longevity in the blood as an important basic property of colloidal drug delivery systems
Approaches to designing long-circulating nanoparticles
Enhancing efficacy of PEGylated nanoparticles: sheddable coatings
Conclusion
Acknowledgments
Chapter 19: Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies
Abstract
Introduction
Liposomes for the delivery of chemotherapeutics
Targeted delivery of liposomal chemotherapeutics to brain tumors
Practical issues in the development of liposomal formulations of chemotherapeutic drugs
Conclusions and recommendations
Index
No. of pages: 520
Language: English
Published: December 30, 2014
Imprint: Academic Press
Hardback ISBN: 9780124166035
eBook ISBN: 9780124166615
MS
Manmohan Singh
Manmohan Singh, Ph.D. is a well-known expert in the area of vaccine formulations and adjuvant research and has been working in vaccine R&D for the last 20 years. He has authored over 120 peer reviewed manuscripts, review articles and book chapters in this area. Dr. Singh is on the editorial board of 9 International Journals . He is also the editor of several books on vaccine delivery systems and adjuvants. He is currently working as the Head of Global Drug Product Development at Novartis Vaccines in Holly Springs, NC, U.S.A.
Affiliations and expertise
PhD, Head of Global Manufacturing Technology Development & Adjuvant Formulation & Technology, Novartis Vaccines and Diagnostics; Adjunct Professor, University of North Carolina at Chapel Hill
MS
Maya Salnikova
Maya Salnikova, Ph.D. is a well-known expert in the area of biologics, biosimilars and vaccine formulations. She has been working on development of novel formulations for the past 10 years in academia and industry. She has authored over 20 peer reviewed articles and book chapters. Dr. Salnikova is on the board of reviewers for Journal of Pharmaceutical Sciences and has contributed in organizing of international conferences. She is currently working as Drug Product Development Lead at Novartis Vaccines in Holly Springs, NC, U.S.A.
Affiliations and expertise
PhD, Principal Scientist and Formulation Group Leader, Novartis Vaccines and Diagnostics, Holly Springs, NC